{Reference Type}: Case Reports
{Title}: Elevation of the tumor marker CA19-9 in a pancreatic cancer survivor with benign prostatic hyperplasia: A clinical case report.
{Author}: Pendry SD;Singhal N;Neo EL;Foreman D;Winter JM;
{Journal}: Clin Case Rep
{Volume}: 12
{Issue}: 6
{Year}: 2024 Jun
暂无{DOI}: 10.1002/ccr3.8929
{Abstract}: Serum carbohydrate antigen 19-9 (CA19-9) is used for recurrence surveillance in patients with resected pancreatic ductal adenocarcinoma (PDAC). This report describes the association of increasing CA19-9 in a male PDAC survivor with presence of prostatic hyperplasia. Unexplained elevation of CA19-9 in male PDAC survivors might be attributable to benign prostatic conditions.